Brain

Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader…

11 months ago

Nexalin’s Breakthrough DIFS™ Neurostimulation Device Demonstrates Reduction in Blood Pressure while Enhancing Mental Health According to New Landmark Study

HOUSTON, TX, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) the leader…

11 months ago

MYndspan and BIOS Health Partner to Make Consumer-Scale Precision Neuroscience a Reality

LONDON, Feb. 3, 2025 /PRNewswire/ - MYndspan, a pioneer in consumer brain health technology, and BIOS Health, a leader in…

11 months ago

Annovis Bio, Inc. Announces Proposed Public Offering

MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”),…

11 months ago

Human Organs-on-Chips Market to Reach USD 1019 Million by 2031 | 31.2% CAGR Growth Forecast – Valuates Reports

BANGALORE, India, Jan. 31, 2025 /PRNewswire/ -- Human Organs-on-Chips Market is Segmented by Type (Brain-on-a-chip, Liver-on-a-chip, Kidney-on-a-chip, Lung-on-a-chip, Heart-on-a-chip, Intestine-on-a-chip,…

11 months ago

MintNeuro Wins Three UK Government ARIA Awards to Apply Advanced Chip Technology to Neural Devices

 Multi-million-pound funding to drive development of next-gen neural implant, neuromodulation and neurosensing therapeutics for clinical use LONDON, Jan. 31, 2025…

11 months ago

CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference

— Data from the first 16 weeks of the open-label extension phase of the RewinD-LB trial are expected in 1Q…

11 months ago

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era…

11 months ago

Sleep Software Market to Hit USD 1,569.2 Million by 2030 with 10.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Jan. 30, 2025 /PRNewswire/ -- The global sleep software market valued at US$ 776.2 Million in 2023, is forecasted…

11 months ago

Potential Revolution in Healthcare Brewing, Powered by AI Innovation

USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 29, 2025 /PRNewswire/ -- USA News…

11 months ago